Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory”

6,399 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 6,399 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Looking for participantsNCT02203903
What this trial is testing

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Who this might be right for
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Catherine Bollard 50
Testing effectiveness (Phase 2)UnknownNCT04296786
What this trial is testing

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Who this might be right for
Cutaneous T-cell Lymphoma
Peking Union Medical College Hospital 52
Testing effectiveness (Phase 2)WithdrawnNCT00005969
What this trial is testing

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Early research (Phase 1)Ended earlyNCT05712278
What this trial is testing

Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukaemia
Sanofi 7
Early research (Phase 1)UnknownNCT05474885
What this trial is testing

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Who this might be right for
Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
iCell Gene Therapeutics 15
Testing effectiveness (Phase 2)Study completedNCT00048555
What this trial is testing

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Biogen 90
Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT07341191
What this trial is testing

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Who this might be right for
Mantle Cell Lymphoma
Canadian Cancer Trials Group 40
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Very early researchLooking for participantsNCT07144020
What this trial is testing

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05996185
What this trial is testing

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Who this might be right for
T Cell LymphomaT-cell Lymphoma
Yale University 22
Early research (Phase 1)Study completedNCT03441555
What this trial is testing

Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
AbbVie 36
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Testing effectiveness (Phase 2)UnknownNCT05274997
What this trial is testing

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Who this might be right for
Peripheral T/NK Cell Lymphoma (R/R PTCL)
Shanghai YingLi Pharmaceutical Co. Ltd. 97
Load More Results